{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T22:28:14Z","timestamp":1792621694650,"version":"4.5.0"},"reference-count":157,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,7,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Our understanding of the genetics of acute myeloid leukemia (AML) development from myelodysplastic syndrome (MDS) has advanced significantly as a result of next-generation sequencing technology. Although differences in cell biology and maturation exist between MDS and AML secondary to MDS, these 2 diseases are genetically related. MDS and secondary AML cells harbor mutations in many of the same genes and functional categories, including chromatin modification, DNA methylation, RNA splicing, cohesin complex, transcription factors, cell signaling, and DNA damage, confirming that they are a disease continuum. Differences in the frequency of mutated genes in MDS and secondary AML indicate that the order of mutation acquisition is not random during progression. In almost every case, disease progression is associated with clonal evolution, typically defined by the expansion or emergence of a subclone with a unique set of mutations. Monitoring tumor burden and clonal evolution using sequencing provides advantages over using the blast count, which underestimates tumor burden, and could allow for early detection of disease progression prior to clinical deterioration. In this review, we outline advances in the study of MDS to secondary AML progression, with a focus on the genetics of progression, and discuss the advantages of incorporating molecular genetic data in the diagnosis, classification, and monitoring of MDS to secondary AML progression. Because sequencing is becoming routine in the clinic, ongoing research is needed to define the optimal assay to use in different clinical situations and how the data can be used to improve outcomes for patients with MDS and secondary AML.<\/jats:p>","DOI":"10.1182\/blood.2019000942","type":"journal-article","created":{"date-parts":[[2020,5,19]],"date-time":"2020-05-19T20:54:44Z","timestamp":1589921684000},"page":"50-60","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":167,"title":["Genetics of progression from MDS to secondary leukemia"],"prefix":"10.1182","volume":"136","author":[{"given":"Andrew J.","family":"Menssen","sequence":"first","affiliation":[{"name":"Division of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, MO; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7753-1091","authenticated-orcid":false,"given":"Matthew J.","family":"Walter","sequence":"first","affiliation":[{"name":"Division of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, MO; and"},{"name":"Siteman Cancer Center, Washington University, St. Louis, MO"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"10","key":"2020070211300729800_B1","doi-asserted-by":"crossref","first-page":"4841","DOI":"10.1182\/blood-2007-08-078139","article-title":"Myelodysplastic syndromes","volume":"111","author":"Nimer","year":"2008","journal-title":"Blood"},{"issue":"19","key":"2020070211300729800_B2","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1056\/NEJMra0902908","article-title":"Myelodysplastic syndromes","volume":"361","author":"Tefferi","year":"2009","journal-title":"N Engl J Med"},{"key":"2020070211300729800_B3","volume-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","author":"Swerdlow","year":"2008","edition":"4th ed"},{"issue":"26","key":"2020070211300729800_B4","doi-asserted-by":"crossref","first-page":"7121","DOI":"10.1182\/blood-2011-02-337964","article-title":"Incidence of the myelodysplastic syndromes using a novel claims-based algorithm: high number of uncaptured cases by cancer registries","volume":"117","author":"Cogle","year":"2011","journal-title":"Blood"},{"issue":"17","key":"2020070211300729800_B5","doi-asserted-by":"crossref","first-page":"2847","DOI":"10.1200\/JCO.2009.25.2395","article-title":"Incidence and clinical complications of myelodysplastic syndromes among United States Medicare beneficiaries","volume":"28","author":"Goldberg","year":"2010","journal-title":"J Clin Oncol"},{"issue":"7 suppl","key":"2020070211300729800_B6","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/j.amjmed.2012.04.014","article-title":"Epidemiology of myelodysplastic syndromes","volume":"125","author":"Ma","year":"2012","journal-title":"Am J Med"},{"key":"2020070211300729800_B7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.blre.2018.09.001","article-title":"Epidemiology of myelodysplastic syndromes: why characterizing the beast is a prerequisite to taming it","volume":"34","author":"Zeidan","year":"2019","journal-title":"Blood Rev"},{"issue":"31","key":"2020070211300729800_B8","doi-asserted-by":"crossref","first-page":"3641","DOI":"10.1200\/JCO.2014.60.0890","article-title":"Epidemiology and clinical significance of secondary and therapy-related acute myeloid leukemia: a national population-based cohort study","volume":"33","author":"Granfeldt \u00d8stg\u00e5rd","year":"2015","journal-title":"J Clin Oncol"},{"issue":"3","key":"2020070211300729800_B9","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1002\/ajh.23908","article-title":"Characterization and prognostic features of secondary acute myeloid leukemia in a population-based setting: a report from the Swedish Acute Leukemia Registry","volume":"90","author":"Huleg\u00e5rdh","year":"2015","journal-title":"Am J Hematol"},{"issue":"10","key":"2020070211300729800_B10","first-page":"937","article-title":"The incidence of secondary leukemias","volume":"84","author":"Leone","year":"1999","journal-title":"Haematologica"},{"issue":"14","key":"2020070211300729800_B11","doi-asserted-by":"crossref","first-page":"3217","DOI":"10.1002\/cncr.24367","article-title":"Survival is poorer in patients with secondary core-binding factor acute myelogenous leukemia compared with de novo core-binding factor leukemia","volume":"115","author":"Borthakur","year":"2009","journal-title":"Cancer"},{"issue":"9","key":"2020070211300729800_B12","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1002\/ajh.23772","article-title":"Characteristics of acute myeloid leukemia with myelodysplasia-related changes: A retrospective analysis in a cohort of Chinese patients","volume":"89","author":"Xu","year":"2014","journal-title":"Am J Hematol"},{"issue":"26","key":"2020070211300729800_B13","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1056\/NEJMoa1409405","article-title":"Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence","volume":"371","author":"Genovese","year":"2014","journal-title":"N Engl J Med"},{"issue":"26","key":"2020070211300729800_B14","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.1056\/NEJMoa1408617","article-title":"Age-related clonal hematopoiesis associated with adverse outcomes","volume":"371","author":"Jaiswal","year":"2014","journal-title":"N Engl J Med"},{"issue":"22","key":"2020070211300729800_B15","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1056\/NEJMoa1301689","article-title":"Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia","volume":"368","author":"Ley","year":"2013","journal-title":"N Engl J Med"},{"issue":"8","key":"2020070211300729800_B16","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1038\/leu.2016.130","article-title":"\u201cCHIP\u201dping away at clonal hematopoiesis","volume":"30","author":"Link","year":"2016","journal-title":"Leukemia"},{"issue":"12","key":"2020070211300729800_B17","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1056\/NEJMoa1106968","article-title":"Clonal architecture of secondary acute myeloid leukemia","volume":"366","author":"Walter","year":"2012","journal-title":"N Engl J Med"},{"issue":"6","key":"2020070211300729800_B18","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1038\/leu.2013.58","article-title":"Clonal diversity of recurrently mutated genes in myelodysplastic syndromes","volume":"27","author":"Walter","year":"2013","journal-title":"Leukemia"},{"issue":"2","key":"2020070211300729800_B19","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.cell.2012.06.023","article-title":"The origin and evolution of mutations in acute myeloid leukemia","volume":"150","author":"Welch","year":"2012","journal-title":"Cell"},{"issue":"12","key":"2020070211300729800_B20","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1038\/nm.3733","article-title":"Age-related mutations associated with clonal hematopoietic expansion and malignancies","volume":"20","author":"Xie","year":"2014","journal-title":"Nat Med"},{"issue":"1","key":"2020070211300729800_B21","doi-asserted-by":"crossref","first-page":"12484","DOI":"10.1038\/ncomms12484","article-title":"Clonal haematopoiesis harbouring AML-associated mutations is ubiquitous in healthy adults","volume":"7","author":"Young","year":"2016","journal-title":"Nat Commun"},{"issue":"12","key":"2020070211300729800_B22","doi-asserted-by":"crossref","first-page":"2410","DOI":"10.3324\/haematol.2018.215269","article-title":"Clonal hematopoiesis and risk of acute myeloid leukemia","volume":"104","author":"Young","year":"2019","journal-title":"Haematologica"},{"issue":"1","key":"2020070211300729800_B23","doi-asserted-by":"crossref","first-page":"15099","DOI":"10.1038\/ncomms15099","article-title":"Clonal evolution in myelodysplastic syndromes","volume":"8","author":"da Silva-Coelho","year":"2017","journal-title":"Nat Commun"},{"issue":"9","key":"2020070211300729800_B24","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1182\/blood-2015-11-679167","article-title":"Mutational hierarchies in myelodysplastic syndromes dynamically adapt and evolve upon therapy response and failure","volume":"128","author":"Mossner","year":"2016","journal-title":"Blood"},{"issue":"6","key":"2020070211300729800_B25","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1182\/blood-2017-02-769869","article-title":"Clonal hematopoiesis, with and without candidate driver mutations, is common in the elderly","volume":"130","author":"Zink","year":"2017","journal-title":"Blood"},{"issue":"1","key":"2020070211300729800_B26","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/s41591-018-0267-4","article-title":"Myelodysplastic syndrome progression to acute myeloid leukemia at the stem cell level [published correction appears in Nat Med. 2019;25(3):529]","volume":"25","author":"Chen","year":"2019","journal-title":"Nat Med"},{"issue":"6","key":"2020070211300729800_B27","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1182\/blood-2015-04-640128","article-title":"Effect of lenalidomide treatment on clonal architecture of myelodysplastic syndromes without 5q deletion","volume":"127","author":"Chesnais","year":"2016","journal-title":"Blood"},{"issue":"6","key":"2020070211300729800_B28","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1182\/blood.V89.6.2079","article-title":"International scoring system for evaluating prognosis in myelodysplastic syndromes","volume":"89","author":"Greenberg","year":"1997","journal-title":"Blood"},{"issue":"12","key":"2020070211300729800_B29","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1182\/blood-2012-03-420489","article-title":"Revised international prognostic scoring system for myelodysplastic syndromes","volume":"120","author":"Greenberg","year":"2012","journal-title":"Blood"},{"issue":"9","key":"2020070211300729800_B30","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1182\/blood-2008-10-182782","article-title":"Clinical characterization of acute myeloid leukemia with myelodysplasia-related changes as defined by the 2008 WHO classification system","volume":"113","author":"Weinberg","year":"2009","journal-title":"Blood"},{"issue":"10","key":"2020070211300729800_B31","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1016\/j.leukres.2005.12.001","article-title":"Are myelodysplastic syndromes \u201ccancer\u201d? Unexpected adverse consequences of linguistic ambiguity","volume":"30","author":"Steensma","year":"2006","journal-title":"Leuk Res"},{"issue":"2","key":"2020070211300729800_B32","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1182\/blood.V99.2.725","article-title":"Language and the clonal myeloid diseases","volume":"99","author":"Lichtman","year":"2002","journal-title":"Blood"},{"issue":"3","key":"2020070211300729800_B33","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/S0145-2126(98)00166-0","article-title":"Myelodysplastic syndrome: a search for minimal diagnostic criteria","volume":"23","author":"Ramos","year":"1999","journal-title":"Leuk Res"},{"issue":"4","key":"2020070211300729800_B34","doi-asserted-by":"crossref","first-page":"568","DOI":"10.3324\/haematol.2012.071449","article-title":"Reproducibility of the World Health Organization 2008 criteria for myelodysplastic syndromes","volume":"98","author":"Senent","year":"2013","journal-title":"Haematologica"},{"issue":"5","key":"2020070211300729800_B35","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/S0145-2126(96)00110-5","article-title":"Morphological changes and apoptosis in bone marrow from patients with myelodysplastic syndromes treated with granulocyte-CSF and erythropoietin","volume":"21","author":"Hellstr\u00f6m-Lindberg","year":"1997","journal-title":"Leuk Res"},{"issue":"12","key":"2020070211300729800_B36","doi-asserted-by":"crossref","first-page":"3932","DOI":"10.1182\/blood.V96.12.3932","article-title":"The role of apoptosis, proliferation, and the Bcl-2-related proteins in the myelodysplastic syndromes and acute myeloid leukemia secondary to MDS","volume":"96","author":"Parker","year":"2000","journal-title":"Blood"},{"issue":"1-2","key":"2020070211300729800_B37","doi-asserted-by":"crossref","first-page":"111","DOI":"10.3109\/10428199709068277","article-title":"Excessive proliferation matched by excessive apoptosis in myelodysplastic syndromes: the cause-effect relationship","volume":"27","author":"Raza","year":"1997","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"2020070211300729800_B38","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1182\/blood.V86.1.268.bloodjournal861268","article-title":"Apoptosis in bone marrow biopsy samples involving stromal and hematopoietic cells in 50 patients with myelodysplastic syndromes","volume":"86","author":"Raza","year":"1995","journal-title":"Blood"},{"issue":"12","key":"2020070211300729800_B39","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1016\/j.leukres.2007.06.013","article-title":"Bone marrow mononuclear cells of MDS patients are characterized by in vitro proliferation and increased apoptosis independently of stromal interactions","volume":"31","author":"Span","year":"2007","journal-title":"Leuk Res"},{"issue":"3","key":"2020070211300729800_B40","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1182\/blood-2002-06-1774","article-title":"Granulocyte colony-stimulating factor inhibits spontaneous cytochrome c release and mitochondria-dependent apoptosis of myelodysplastic syndrome hematopoietic progenitors","volume":"101","author":"Tehranchi","year":"2003","journal-title":"Blood"},{"issue":"25","key":"2020070211300729800_B41","doi-asserted-by":"crossref","first-page":"2960","DOI":"10.1182\/blood-2016-07-730556","article-title":"The NLRP3 inflammasome functions as a driver of the myelodysplastic syndrome phenotype","volume":"128","author":"Basiorka","year":"2016","journal-title":"Blood"},{"issue":"2","key":"2020070211300729800_B42","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1182\/blood-2018-05-847335","article-title":"Increased Ripk1-mediated bone marrow necroptosis leads to myelodysplasia and bone marrow failure in mice","volume":"133","author":"Wagner","year":"2019","journal-title":"Blood"},{"issue":"3","key":"2020070211300729800_B43","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/BF02982044","article-title":"Biological significance of proliferation, apoptosis, cytokines, and monocyte\/macrophage cells in bone marrow biopsies of 145 patients with myelodysplastic syndrome","volume":"75","author":"Allampallam","year":"2002","journal-title":"Int J Hematol"},{"issue":"11","key":"2020070211300729800_B44","doi-asserted-by":"crossref","first-page":"4595","DOI":"10.1172\/JCI67580","article-title":"Induction of myelodysplasia by myeloid-derived suppressor cells","volume":"123","author":"Chen","year":"2013","journal-title":"J Clin Invest"},{"issue":"7","key":"2020070211300729800_B45","doi-asserted-by":"crossref","first-page":"2640","DOI":"10.1182\/blood.V88.7.2640.bloodjournal8872640","article-title":"Indication of an involvement of interleukin-1 beta converting enzyme-like protease in intramedullary apoptotic cell death in the bone marrow of patients with myelodysplastic syndromes","volume":"88","author":"Mundle","year":"1996","journal-title":"Blood"},{"issue":"10","key":"2020070211300729800_B46","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1080\/10428190802322919","article-title":"Inhibition of p38alpha MAPK disrupts the pathological loop of proinflammatory factor production in the myelodysplastic syndrome bone marrow microenvironment [published correction appears in Leuk Lymphoma 2009;50(9):1554]","volume":"49","author":"Navas","year":"2008","journal-title":"Leuk Lymphoma"},{"issue":"13","key":"2020070211300729800_B47","doi-asserted-by":"crossref","first-page":"2991","DOI":"10.1182\/blood-2011-12-380113","article-title":"Demand-adapted regulation of early hematopoiesis in infection and inflammation","volume":"119","author":"Takizawa","year":"2012","journal-title":"Blood"},{"issue":"21","key":"2020070211300729800_B48","doi-asserted-by":"crossref","first-page":"3327","DOI":"10.1182\/blood-2013-07-512855","article-title":"Two splice-factor mutant leukemia subgroups uncovered at the boundaries of MDS and AML using combined gene expression and DNA-methylation profiling","volume":"123","author":"Taskesen","year":"2014","journal-title":"Blood"},{"issue":"24","key":"2020070211300729800_B49","doi-asserted-by":"crossref","first-page":"2642","DOI":"10.1182\/blood-2017-05-783050","article-title":"Gene expression and risk of leukemic transformation in myelodysplasia [published correction appears in Blood 2018;132(8):869-875]","volume":"130","author":"Shiozawa","year":"2017","journal-title":"Blood"},{"issue":"12","key":"2020070211300729800_B50","doi-asserted-by":"crossref","first-page":"2952","DOI":"10.1080\/10428194.2018.1452210","article-title":"Distinct transcriptomic and exomic abnormalities within myelodysplastic syndrome marrow cells","volume":"59","author":"Im","year":"2018","journal-title":"Leuk Lymphoma"},{"issue":"8","key":"2020070211300729800_B51","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/s41408-018-0115-2","article-title":"The prognostic significance of global aberrant alternative splicing in patients with myelodysplastic syndrome","volume":"8","author":"Yang","year":"2018","journal-title":"Blood Cancer J"},{"issue":"1","key":"2020070211300729800_B52","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1182\/blood.V73.1.248.248","article-title":"Clonal analysis of myelodysplastic syndromes: evidence of multipotent stem cell origin","volume":"73","author":"Janssen","year":"1989","journal-title":"Blood"},{"issue":"5671","key":"2020070211300729800_B53","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1038\/274590a0","article-title":"A common progenitor for human myeloid and lymphoid cells","volume":"274","author":"Prchal","year":"1978","journal-title":"Nature"},{"issue":"6","key":"2020070211300729800_B54","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1182\/blood.V63.6.1318.1318","article-title":"Evidence for a multistep pathogenesis of a myelodysplastic syndrome","volume":"63","author":"Raskind","year":"1984","journal-title":"Blood"},{"issue":"12","key":"2020070211300729800_B55","first-page":"4826","article-title":"Second International Workshop on Chromosomes in Leukemia","volume":"40","year":"1980","journal-title":"Cancer Res"},{"issue":"6","key":"2020070211300729800_B56","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1182\/blood.V67.6.1765.1765","article-title":"Prognostic implications of morphology and karyotype in primary myelodysplastic syndromes","volume":"67","author":"Jacobs","year":"1986","journal-title":"Blood"},{"issue":"3","key":"2020070211300729800_B57","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1200\/JCO.1986.4.3.325","article-title":"Clinical and cytogenetic correlations in 63 patients with therapy-related myelodysplastic syndromes and acute nonlymphocytic leukemia: further evidence for characteristic abnormalities of chromosomes no. 5 and 7","volume":"4","author":"Le Beau","year":"1986","journal-title":"J Clin Oncol"},{"issue":"6","key":"2020070211300729800_B58","first-page":"1930","article-title":"Cytogenetic and molecular delineation of a region of chromosome 7 commonly deleted in malignant myeloid diseases","volume":"88","author":"Le Beau","year":"1996","journal-title":"Blood"},{"issue":"5","key":"2020070211300729800_B59","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1002\/1097-0142(197811)42:5<2254::AID-CNCR2820420525>3.0.CO;2-0","article-title":"Chromosome studies in preleukemic states. IV. Myeloproliferative versus cytopenic disorders","volume":"42","author":"Nowell","year":"1978","journal-title":"Cancer"},{"issue":"1","key":"2020070211300729800_B60","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S0308-2261(21)00166-1","article-title":"The karyotype in refractory anaemia and pre-leukaemia","volume":"9","author":"Sokal","year":"1980","journal-title":"Clin Haematol"},{"issue":"4","key":"2020070211300729800_B61","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1182\/blood.V46.4.519.519","article-title":"A new hematologic syndrome with a distinct karyotype: the 5 q--chromosome","volume":"46","author":"Sokal","year":"1975","journal-title":"Blood"},{"issue":"4","key":"2020070211300729800_B62","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1182\/blood.V55.4.636.636","article-title":"Dysmyelopoietic syndrome: sequential clinical and cytogenetic studies","volume":"55","author":"Streuli","year":"1980","journal-title":"Blood"},{"issue":"6","key":"2020070211300729800_B63","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1182\/blood.V67.6.1721.1721","article-title":"Refined chromosome analysis as an independent prognostic indicator in de novo myelodysplastic syndromes","volume":"67","author":"Yunis","year":"1986","journal-title":"Blood"},{"issue":"2","key":"2020070211300729800_B64","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/leu.2013.336","article-title":"Landscape of genetic lesions in 944 patients with myelodysplastic syndromes","volume":"28","author":"Haferlach","year":"2014","journal-title":"Leukemia"},{"issue":"9","key":"2020070211300729800_B65","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1182\/blood-2014-11-610543","article-title":"Acute myeloid leukemia ontogeny is defined by distinct somatic mutations","volume":"125","author":"Lindsley","year":"2015","journal-title":"Blood"},{"issue":"2","key":"2020070211300729800_B66","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1038\/ng.3742","article-title":"Dynamics of clonal evolution in myelodysplastic syndromes","volume":"49","author":"Makishima","year":"2017","journal-title":"Nat Genet"},{"issue":"22","key":"2020070211300729800_B68","doi-asserted-by":"crossref","first-page":"3616","DOI":"10.1182\/blood-2013-08-518886","article-title":"Clinical and biological implications of driver mutations in myelodysplastic syndromes","volume":"122","author":"Papaemmanuil","year":"2013","journal-title":"Blood"},{"issue":"23","key":"2020070211300729800_B69","doi-asserted-by":"crossref","first-page":"8589","DOI":"10.1073\/pnas.1407688111","article-title":"Genomic landscape of CD34+ hematopoietic cells in myelodysplastic syndrome and gene mutation profiles as prognostic markers","volume":"111","author":"Xu","year":"2014","journal-title":"Proc Natl Acad Sci USA"},{"issue":"9","key":"2020070211300729800_B70","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1634\/theoncologist.2013-0099","article-title":"Does a diagnosis of myelogenous leukemia require 20% marrow myeloblasts, and does &lt;5% marrow myeloblasts represent a remission? The history and ambiguity of arbitrary diagnostic boundaries in the understanding of myelodysplasia","volume":"18","author":"Lichtman","year":"2013","journal-title":"Oncologist"},{"issue":"1","key":"2020070211300729800_B71","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bcmd.2015.03.002","article-title":"Distinguishing clonal evolution from so-called secondary acute myelogenous leukemia: Adhering to unifying concepts of the genetic basis of leukemogenesis","volume":"55","author":"Lichtman","year":"2015","journal-title":"Blood Cells Mol Dis"},{"issue":"26","key":"2020070211300729800_B72","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1056\/NEJMoa1013343","article-title":"Clinical effect of point mutations in myelodysplastic syndromes","volume":"364","author":"Bejar","year":"2011","journal-title":"N Engl J Med"},{"issue":"10","key":"2020070211300729800_B73","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1038\/leu.2013.160","article-title":"NRAS mutations with low allele burden have independent prognostic significance for patients with lower risk myelodysplastic syndromes","volume":"27","author":"Murphy","year":"2013","journal-title":"Leukemia"},{"issue":"7","key":"2020070211300729800_B74","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1007\/s00277-008-0483-y","article-title":"Cytogenetic features in myelodysplastic syndromes","volume":"87","author":"Haase","year":"2008","journal-title":"Ann Hematol"},{"issue":"13","key":"2020070211300729800_B75","doi-asserted-by":"crossref","first-page":"4385","DOI":"10.1182\/blood-2007-03-082404","article-title":"New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients","volume":"110","author":"Haase","year":"2007","journal-title":"Blood"},{"issue":"11","key":"2020070211300729800_B76","doi-asserted-by":"crossref","first-page":"e1225","DOI":"10.1371\/journal.pone.0001225","article-title":"SNP array karyotyping allows for the detection of uniparental disomy and cryptic chromosomal abnormalities in MDS\/MPD-U and MPD","volume":"2","author":"Gondek","year":"2007","journal-title":"PLoS One"},{"issue":"11","key":"2020070211300729800_B77","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1016\/j.exphem.2007.08.009","article-title":"Detection of cryptic chromosomal lesions including acquired segmental uniparental disomy in advanced and low-risk myelodysplastic syndromes","volume":"35","author":"Gondek","year":"2007","journal-title":"Exp Hematol"},{"issue":"3","key":"2020070211300729800_B78","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1182\/blood-2007-05-092304","article-title":"Chromosomal lesions and uniparental disomy detected by SNP arrays in MDS, MDS\/MPD, and MDS-derived AML","volume":"111","author":"Gondek","year":"2008","journal-title":"Blood"},{"issue":"9","key":"2020070211300729800_B79","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1038\/leu.2009.82","article-title":"Accurate detection of uniparental disomy and microdeletions by SNP array analysis in myelodysplastic syndromes with normal cytogenetics","volume":"23","author":"Heinrichs","year":"2009","journal-title":"Leukemia"},{"issue":"9","key":"2020070211300729800_B80","doi-asserted-by":"crossref","first-page":"3365","DOI":"10.1182\/blood-2007-03-079673","article-title":"Prevalence and prognostic significance of allelic imbalance by single-nucleotide polymorphism analysis in low-risk myelodysplastic syndromes","volume":"110","author":"Mohamedali","year":"2007","journal-title":"Blood"},{"issue":"1","key":"2020070211300729800_B81","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1053\/j.seminoncol.2011.11.010","article-title":"Single-nucleotide polymorphism array karyotyping in clinical practice: where, when, and how?","volume":"39","author":"Sato-Otsubo","year":"2012","journal-title":"Semin Oncol"},{"issue":"23","key":"2020070211300729800_B67","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","article-title":"Genomic classification and prognosis in acute myeloid leukemia","volume":"374","author":"Papaemmanuil","year":"2016","journal-title":"N Engl J Med"},{"issue":"4","key":"2020070211300729800_B82","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1038\/leu.2016.282","article-title":"Dynamic changes in the clonal structure of MDS and AML in response to epigenetic therapy","volume":"31","author":"Uy","year":"2017","journal-title":"Leukemia"},{"issue":"7367","key":"2020070211300729800_B83","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1038\/nature10496","article-title":"Frequent pathway mutations of splicing machinery in myelodysplasia","volume":"478","author":"Yoshida","year":"2011","journal-title":"Nature"},{"issue":"19","key":"2020070211300729800_B84","doi-asserted-by":"crossref","first-page":"2513","DOI":"10.1182\/bloodadvances.2017010744","article-title":"Cell-lineage level-targeted sequencing to identify acute myeloid leukemia with myelodysplasia-related changes","volume":"2","author":"Yokoyama","year":"2018","journal-title":"Blood Adv"},{"issue":"10","key":"2020070211300729800_B85","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1182\/blood-2016-10-692400","article-title":"Splicing factor gene mutations in hematologic malignancies","volume":"129","author":"Saez","year":"2017","journal-title":"Blood"},{"issue":"1","key":"2020070211300729800_B86","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/nrc.2016.112","article-title":"The genetics of myelodysplastic syndrome: from clonal haematopoiesis to secondary leukaemia","volume":"17","author":"Sperling","year":"2017","journal-title":"Nat Rev Cancer"},{"issue":"7","key":"2020070211300729800_B87","doi-asserted-by":"crossref","first-page":"2548","DOI":"10.1073\/pnas.1324297111","article-title":"Preleukemic mutations in human acute myeloid leukemia affect epigenetic regulators and persist in remission","volume":"111","author":"Corces-Zimmerman","year":"2014","journal-title":"Proc Natl Acad Sci USA"},{"issue":"9","key":"2020070211300729800_B88","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1038\/leu.2017.17","article-title":"The clonal origins of leukemic progression of myelodysplasia","volume":"31","author":"Kim","year":"2017","journal-title":"Leukemia"},{"issue":"10","key":"2020070211300729800_B89","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1038\/leu.2013.165","article-title":"Dynamic acquisition of FLT3 or RAS alterations drive a subset of patients with lower risk MDS to secondary AML","volume":"27","author":"Takahashi","year":"2013","journal-title":"Leukemia"},{"issue":"4","key":"2020070211300729800_B90","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.trecan.2015.10.006","article-title":"Implications of tumor clonal heterogeneity in the era of next-generation sequencing","volume":"1","author":"Jacoby","year":"2015","journal-title":"Trends Cancer"},{"issue":"11","key":"2020070211300729800_B91","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1056\/NEJMoa1804714","article-title":"Mutation clearance after transplantation for myelodysplastic syndrome","volume":"379","author":"Duncavage","year":"2018","journal-title":"N Engl J Med"},{"issue":"7","key":"2020070211300729800_B92","doi-asserted-by":"crossref","first-page":"e1004462","DOI":"10.1371\/journal.pgen.1004462","article-title":"Clonal architecture of secondary acute myeloid leukemia defined by single-cell sequencing","volume":"10","author":"Hughes","year":"2014","journal-title":"PLoS Genet"},{"issue":"3","key":"2020070211300729800_B93","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.ccr.2014.01.031","article-title":"Functional heterogeneity of genetically defined subclones in acute myeloid leukemia","volume":"25","author":"Klco","year":"2014","journal-title":"Cancer Cell"},{"issue":"7382","key":"2020070211300729800_B94","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1038\/nature10738","article-title":"Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing","volume":"481","author":"Ding","year":"2012","journal-title":"Nature"},{"issue":"8","key":"2020070211300729800_B95","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1038\/s41375-018-0193-y","article-title":"Discriminating a common somatic ASXL1 mutation (c.1934dup; p.G646Wfs*12) from artifact in myeloid malignancies using NGS","volume":"32","author":"Alberti","year":"2018","journal-title":"Leukemia"},{"issue":"10","key":"2020070211300729800_B96","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1182\/blood-2018-10-844621","article-title":"Genetics of MDS","volume":"133","author":"Ogawa","year":"2019","journal-title":"Blood"},{"issue":"1","key":"2020070211300729800_B97","doi-asserted-by":"crossref","first-page":"5901","DOI":"10.1038\/ncomms6901","article-title":"Combining gene mutation with gene expression data improves outcome prediction in myelodysplastic syndromes","volume":"6","author":"Gerstung","year":"2015","journal-title":"Nat Commun"},{"issue":"10","key":"2020070211300729800_B98","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1038\/ng.2731","article-title":"Recurrent mutations in multiple components of the cohesin complex in myeloid neoplasms","volume":"45","author":"Kon","year":"2013","journal-title":"Nat Genet"},{"issue":"2","key":"2020070211300729800_B99","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.ccell.2018.07.003","article-title":"Synthetic lethal and convergent biological effects of cancer-associated spliceosomal gene mutations","volume":"34","author":"Lee","year":"2018","journal-title":"Cancer Cell"},{"key":"2020070211300729800_B100","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.semcancer.2017.07.009","article-title":"Epigenetics in myelodysplastic syndromes","volume":"51","author":"Heuser","year":"2018","journal-title":"Semin Cancer Biol"},{"issue":"3","key":"2020070211300729800_B101","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1038\/leu.2013.343","article-title":"Epigenetics of myelodysplastic syndromes","volume":"28","author":"Itzykson","year":"2014","journal-title":"Leukemia"},{"issue":"8","key":"2020070211300729800_B102","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/j.celrep.2015.02.005","article-title":"Leukemia-associated somatic mutations drive distinct patterns of age-related clonal hemopoiesis","volume":"10","author":"McKerrell","year":"2015","journal-title":"Cell Rep"},{"issue":"1","key":"2020070211300729800_B103","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1182\/blood-2015-03-631747","article-title":"Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes","volume":"126","author":"Steensma","year":"2015","journal-title":"Blood"},{"issue":"11","key":"2020070211300729800_B104","doi-asserted-by":"crossref","first-page":"e438","DOI":"10.3324\/haematol.2015.129510","article-title":"DNMT3A mutations occur early or late in patients with myeloproliferative neoplasms and mutation order influences phenotype","volume":"100","author":"Nangalia","year":"2015","journal-title":"Haematologica"},{"issue":"7","key":"2020070211300729800_B105","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1056\/NEJMoa1412098","article-title":"Effect of mutation order on myeloproliferative neoplasms","volume":"372","author":"Ortmann","year":"2015","journal-title":"N Engl J Med"},{"issue":"5","key":"2020070211300729800_B106","doi-asserted-by":"crossref","first-page":"98962","DOI":"10.1172\/jci.insight.98962","article-title":"Subclones dominate at MDS progression following allogeneic hematopoietic cell transplant","volume":"3","author":"Jacoby","year":"2018","journal-title":"JCI Insight"},{"issue":"4","key":"2020070211300729800_B107","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.cell.2013.01.019","article-title":"Evolution and impact of subclonal mutations in chronic lymphocytic leukemia","volume":"152","author":"Landau","year":"2013","journal-title":"Cell"},{"issue":"13","key":"2020070211300729800_B108","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1182\/blood-2018-11-835405","article-title":"Clonal approaches to understanding the impact of mutations on hematologic disease development","volume":"133","author":"Nangalia","year":"2019","journal-title":"Blood"},{"issue":"8","key":"2020070211300729800_B109","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1056\/NEJM198708203170802","article-title":"Clonal development, stem-cell differentiation, and clinical remissions in acute nonlymphocytic leukemia","volume":"317","author":"Fialkow","year":"1987","journal-title":"N Engl J Med"},{"issue":"1","key":"2020070211300729800_B110","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1182\/blood-2001-12-0188","article-title":"Involvement and functional impairment of the CD34(+)CD38(\u2212)Thy-1(+) hematopoietic stem cell pool in myelodysplastic syndromes with trisomy 8","volume":"100","author":"Nilsson","year":"2002","journal-title":"Blood"},{"issue":"8","key":"2020070211300729800_B111","doi-asserted-by":"crossref","first-page":"3011","DOI":"10.1073\/pnas.1222861110","article-title":"Hematopoietic stem cell and progenitor cell mechanisms in myelodysplastic syndromes","volume":"110","author":"Pang","year":"2013","journal-title":"Proc Natl Acad Sci USA"},{"issue":"11","key":"2020070211300729800_B112","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1056\/NEJMoa0912228","article-title":"Persistent malignant stem cells in del(5q) myelodysplasia in remission","volume":"363","author":"Tehranchi","year":"2010","journal-title":"N Engl J Med"},{"issue":"10","key":"2020070211300729800_B113","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.1182\/blood-2011-12-399683","article-title":"Stem and progenitor cells in myelodysplastic syndromes show aberrant stage-specific expansion and harbor genetic and epigenetic alterations","volume":"120","author":"Will","year":"2012","journal-title":"Blood"},{"issue":"6","key":"2020070211300729800_B114","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1016\/j.ccr.2014.03.036","article-title":"Myelodysplastic syndromes are propagated by rare and distinct human cancer stem cells in vivo [published corrections appear in Cancer Cell. 2014;25(6):861 and 2015;27(4):603-605]","volume":"25","author":"Woll","year":"2014","journal-title":"Cancer Cell"},{"issue":"7","key":"2020070211300729800_B115","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1182\/blood-2017-03-776070","article-title":"SF3B1-initiating mutations in MDS-RSs target lymphomyeloid hematopoietic stem cells","volume":"130","author":"Mortera-Blanco","year":"2017","journal-title":"Blood"},{"issue":"6","key":"2020070211300729800_B116","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1182\/blood.V96.6.2012","article-title":"Isolation and characterization of hematopoietic progenitor\/stem cells in 5q-deleted myelodysplastic syndromes: evidence for involvement at the hematopoietic stem cell level","volume":"96","author":"Nilsson","year":"2000","journal-title":"Blood"},{"issue":"14","key":"2020070211300729800_B117","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1056\/NEJMoa061292","article-title":"Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion","volume":"355","author":"List","year":"2006","journal-title":"N Engl J Med"},{"issue":"6","key":"2020070211300729800_B118","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1056\/NEJMoa041668","article-title":"Efficacy of lenalidomide in myelodysplastic syndromes","volume":"352","author":"List","year":"2005","journal-title":"N Engl J Med"},{"issue":"15","key":"2020070211300729800_B119","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1200\/JCO.2010.31.8576","article-title":"TP53 mutations in low-risk myelodysplastic syndromes with del(5q) predict disease progression","volume":"29","author":"J\u00e4dersten","year":"2011","journal-title":"J Clin Oncol"},{"issue":"8","key":"2020070211300729800_B120","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1002\/cncr.21792","article-title":"Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study","volume":"106","author":"Kantarjian","year":"2006","journal-title":"Cancer"},{"issue":"10","key":"2020070211300729800_B121","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1200\/JCO.2002.04.117","article-title":"Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B","volume":"20","author":"Silverman","year":"2002","journal-title":"J Clin Oncol"},{"issue":"3","key":"2020070211300729800_B122","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1182\/blood-2015-01-621664","article-title":"International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with &gt;30% blasts","volume":"126","author":"Dombret","year":"2015","journal-title":"Blood"},{"issue":"3","key":"2020070211300729800_B123","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S1470-2045(09)70003-8","article-title":"Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study","volume":"10","author":"Fenaux","year":"2009","journal-title":"Lancet Oncol"},{"issue":"4","key":"2020070211300729800_B124","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1200\/JCO.2009.23.8329","article-title":"Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia","volume":"28","author":"Fenaux","year":"2010","journal-title":"J Clin Oncol"},{"issue":"17","key":"2020070211300729800_B125","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1182\/blood-2014-06-582809","article-title":"TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients","volume":"124","author":"Bejar","year":"2014","journal-title":"Blood"},{"issue":"7","key":"2020070211300729800_B126","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1038\/leu.2011.71","article-title":"Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias","volume":"25","author":"Itzykson","year":"2011","journal-title":"Leukemia"},{"issue":"5","key":"2020070211300729800_B127","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1038\/leu.2011.342","article-title":"DNMT3A mutations and response to the hypomethylating agent decitabine in acute myeloid leukemia","volume":"26","author":"Metzeler","year":"2012","journal-title":"Leukemia"},{"issue":"1","key":"2020070211300729800_B128","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/leu.2013.269","article-title":"Impact of molecular mutations on treatment response to DNMT inhibitors in myelodysplasia and related neoplasms","volume":"28","author":"Traina","year":"2014","journal-title":"Leukemia"},{"issue":"21","key":"2020070211300729800_B129","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1056\/NEJMoa1605949","article-title":"TP53 and decitabine in acute myeloid leukemia and myelodysplastic syndromes","volume":"375","author":"Welch","year":"2016","journal-title":"N Engl J Med"},{"issue":"9","key":"2020070211300729800_B130","doi-asserted-by":"crossref","first-page":"4681","DOI":"10.1073\/pnas.94.9.4681","article-title":"Mutagenicity of 5-aza-2\u2032-deoxycytidine is mediated by the mammalian DNA methyltransferase","volume":"94","author":"Jackson-Grusby","year":"1997","journal-title":"Proc Natl Acad Sci USA"},{"issue":"5","key":"2020070211300729800_B131","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1038\/leu.2012.312","article-title":"Azacitidine fails to eradicate leukemic stem\/progenitor cell populations in patients with acute myeloid leukemia and myelodysplasia","volume":"27","author":"Craddock","year":"2013","journal-title":"Leukemia"},{"issue":"2","key":"2020070211300729800_B132","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1182\/blood-2004-01-0338","article-title":"A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome","volume":"104","author":"Cutler","year":"2004","journal-title":"Blood"},{"issue":"19","key":"2020070211300729800_B133","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1200\/JCO.2016.70.7349","article-title":"Dose-reduced versus standard conditioning followed by allogeneic stem-cell transplantation for patients with myelodysplastic syndrome: a prospective randomized phase III study of the EBMT (RICMAC Trial)","volume":"35","author":"Kr\u00f6ger","year":"2017","journal-title":"J Clin Oncol"},{"issue":"11","key":"2020070211300729800_B134","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1200\/JCO.2016.70.7091","article-title":"Myeloablative versus reduced-intensity hematopoietic cell transplantation for acute myeloid leukemia and myelodysplastic syndromes","volume":"35","author":"Scott","year":"2017","journal-title":"J Clin Oncol"},{"issue":"1","key":"2020070211300729800_B135","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1182\/blood-2002-09-2768","article-title":"Myeloid and monocytic dyspoiesis as determined by flow cytometric scoring in myelodysplastic syndrome correlates with the IPSS and with outcome after hematopoietic stem cell transplantation","volume":"102","author":"Wells","year":"2003","journal-title":"Blood"},{"issue":"2","key":"2020070211300729800_B136","doi-asserted-by":"crossref","first-page":"201","DOI":"10.3324\/haematol.2012.066787","article-title":"Serial assessment of suspected myelodysplastic syndromes: significance of flow cytometric findings validated by cytomorphology, cytogenetics, and molecular genetics","volume":"98","author":"Kern","year":"2013","journal-title":"Haematologica"},{"issue":"7","key":"2020070211300729800_B137","doi-asserted-by":"crossref","first-page":"2681","DOI":"10.1182\/blood-2008-05-153700","article-title":"Validation of a flow cytometric scoring system as a prognostic indicator for posttransplantation outcome in patients with myelodysplastic syndrome","volume":"112","author":"Scott","year":"2008","journal-title":"Blood"},{"issue":"8","key":"2020070211300729800_B138","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.3324\/haematol.2011.048421","article-title":"Multicenter validation of a reproducible flow cytometric score for the diagnosis of low-grade myelodysplastic syndromes: results of a European LeukemiaNET study","volume":"97","author":"Della Porta","year":"2012","journal-title":"Haematologica"},{"issue":"8","key":"2020070211300729800_B139","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.3324\/haematol.2009.008532","article-title":"Diagnostic utility of flow cytometry in low-grade myelodysplastic syndromes: a prospective validation study","volume":"94","author":"Ogata","year":"2009","journal-title":"Haematologica"},{"issue":"9","key":"2020070211300729800_B140","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1038\/leu.2014.191","article-title":"Revisiting guidelines for integration of flow cytometry results in the WHO classification of myelodysplastic syndromes-proposal from the International\/European LeukemiaNet Working Group for Flow Cytometry in MDS","volume":"28","author":"Porwit","year":"2014","journal-title":"Leukemia"},{"issue":"3","key":"2020070211300729800_B141","doi-asserted-by":"crossref","first-page":"472","DOI":"10.3109\/10428194.2012.718341","article-title":"Rationale for the clinical application of flow cytometry in patients with myelodysplastic syndromes: position paper of an International Consortium and the European LeukemiaNet Working Group","volume":"54","author":"van de Loosdrecht","year":"2013","journal-title":"Leuk Lymphoma"},{"issue":"24","key":"2020070211300729800_B142","doi-asserted-by":"crossref","first-page":"4642","DOI":"10.1200\/JCO.2003.04.036","article-title":"Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia [published correction appears in J Clin Oncol. 2004;22(3):576]","volume":"21","author":"Cheson","year":"2003","journal-title":"J Clin Oncol"},{"issue":"2","key":"2020070211300729800_B143","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1182\/blood-2005-10-4149","article-title":"Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia","volume":"108","author":"Cheson","year":"2006","journal-title":"Blood"},{"issue":"3","key":"2020070211300729800_B144","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1038\/s41375-018-0367-7","article-title":"Rethinking clinical trial endpoints in myelodysplastic syndromes","volume":"33","author":"Sekeres","year":"2019","journal-title":"Leukemia"},{"issue":"23","key":"2020070211300729800_B145","doi-asserted-by":"crossref","first-page":"9530","DOI":"10.1073\/pnas.1105422108","article-title":"Detection and quantification of rare mutations with massively parallel sequencing","volume":"108","author":"Kinde","year":"2011","journal-title":"Proc Natl Acad Sci USA"},{"issue":"36","key":"2020070211300729800_B146","doi-asserted-by":"crossref","first-page":"14508","DOI":"10.1073\/pnas.1208715109","article-title":"Detection of ultra-rare mutations by next-generation sequencing","volume":"109","author":"Schmitt","year":"2012","journal-title":"Proc Natl Acad Sci USA"},{"issue":"11","key":"2020070211300729800_B147","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.3324\/haematol.2009.007765","article-title":"Monitoring of donor chimerism in sorted CD34+ peripheral blood cells allows the sensitive detection of imminent relapse after allogeneic stem cell transplantation","volume":"94","author":"Bornh\u00e4user","year":"2009","journal-title":"Haematologica"},{"issue":"12","key":"2020070211300729800_B148","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1038\/bmt.2012.70","article-title":"Evaluation of BM cytomorphology after allo-SCT in patients with AML","volume":"47","author":"Christopeit","year":"2012","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"2020070211300729800_B149","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/bmt.2012.161","article-title":"Evaluation of BM cytomorphology after allo-SCT in patients with MDS","volume":"48","author":"Christopeit","year":"2013","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"2020070211300729800_B150","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1002\/ajh.21340","article-title":"Minimal residual disease monitoring after allogeneic transplantation may help to individualize post-transplant therapeutic strategies in acute myeloid malignancies","volume":"84","author":"D\u00edez-Campelo","year":"2009","journal-title":"Am J Hematol"},{"issue":"5","key":"2020070211300729800_B151","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1038\/bmt.2010.179","article-title":"Early detection of relapse in patients with myelodysplastic syndrome after allo-SCT","volume":"46","author":"Tobiasson","year":"2011","journal-title":"Bone Marrow Transplant"},{"issue":"12","key":"2020070211300729800_B152","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1016\/S1470-2045(18)30580-1","article-title":"Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trial","volume":"19","author":"Platzbecker","year":"2018","journal-title":"Lancet Oncol"},{"issue":"3","key":"2020070211300729800_B153","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/leu.2011.234","article-title":"Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial","volume":"26","author":"Platzbecker","year":"2012","journal-title":"Leukemia"},{"issue":"8","key":"2020070211300729800_B154","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1038\/bmt.2013.2","article-title":"CD34(+) lineage specific donor cell chimerism for the diagnosis and treatment of impending relapse of AML or myelodysplastic syndrome after allo-SCT","volume":"48","author":"Rosenow","year":"2013","journal-title":"Bone Marrow Transplant"},{"issue":"6","key":"2020070211300729800_B155","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1038\/leu.2013.7","article-title":"Azacitidine and donor lymphocyte infusions as first salvage therapy for relapse of AML or MDS after allogeneic stem cell transplantation","volume":"27","author":"Schroeder","year":"2013","journal-title":"Leukemia"},{"issue":"6","key":"2020070211300729800_B156","doi-asserted-by":"crossref","first-page":"e216","DOI":"10.3324\/haematol.2016.162909","article-title":"Mutational analysis in serial marrow samples during azacitidine treatment in patients with post-transplant relapse of acute myeloid leukemia or myelodysplastic syndromes","volume":"102","author":"Woo","year":"2017","journal-title":"Haematologica"},{"issue":"15","key":"2020070211300729800_B157","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1182\/blood-2018-04-848028","article-title":"Next-generation sequencing-based posttransplant monitoring of acute myeloid leukemia identifies patients at high risk of relapse","volume":"132","author":"Kim","year":"2018","journal-title":"Blood"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/136\/1\/50\/1747573\/bloodbld2019000942c.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/136\/1\/50\/1747573\/bloodbld2019000942c.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,24]],"date-time":"2022-10-24T04:05:25Z","timestamp":1666584325000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/136\/1\/50\/456027\/Genetics-of-progression-from-MDS-to-secondary"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,2]]},"references-count":157,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,7,2]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2019000942","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,2]]}}}